U-PLEX®

Human MIF

Product Options	Catalog Number	Description
Multiplex	K15067M, K25067M K151AEM, K251AEM K151ACM, K251ACM	U-PLEX Biomarker Group 1 (human) U-PLEX Immuno-Oncology Group 1 (human) U-PLEX Metabolic Group 1 (human)
Singleplex	K151XJK-1/-2/-4	U-PLEX Human MIF Assay with SECTOR™ plates
	K151XJK-21/-22/-24	U-PLEX Human MIF Assay with QuickPlex Ultra™ plates
	K251XJK-2/-4	U-PLEX Human MIF Assay with 384-well plates
Antibody Set	B21XJ-2/-3	U-PLEX Human MIF Antibody Set
Protocol	U-PLEX Product Inserts are available at http://www.mesoscale.com	

The MESO SCALE DISCOVERY® U-PLEX platform was designed to provide ultimate flexibility for detection of biomarkers in a wide variety of sample types. This datasheet provides the representative performance of the U-PLEX® Human MIF Assay tested on U-PLEX 96-well SECTOR plates run as a multiplex. The data do not represent the product specifications. Under your experimental conditions, the assay may perform differently from the representative data. U-PLEX assays are offered in either singleplex or multiplex; both are available on 96- or 384-well plates. See a U-PLEX product insert for instrument compatibility.

Representative Calibration Curve and Sensitivity

Assay	Median LLOD (pg/mL)	LLOD Range (pg/mL)
MIF	4.3	2.9-6.3

The Calibrator curve was fitted with a 4-parameter logistic model with a $1/Y^2$ weighting. The lower limit of detection (LLOD) is a calculated concentration corresponding to 2.5 standard deviations above the background (zero Calibrator).

Precision

Control	Average Conc. (pg/mL)	Average Intra-run Conc. (%CV)	Inter-run Conc. (%CV)
High	2,150	5.8	14.0
Mid	478	6.3	14.6
Low	69	8.8	13.6

Controls were made by spiking Calibrator into assay diluent at 3 levels within the quantitative range of the assay. Average intra-run concentration %CV is the average %CV of the control replicates within an individual run. Inter-run concentration %CV is the variability of controls across multiple runs.

Spot the Difference®

MSD® U-PLEX Human MIF

Tested Samples

Sample Type	Serum (N=10)	Plasma (N=10)
Median (pg/mL)	6,170	7,440
Range (pg/mL)	2,990-12,300	1,910-13,000
% Detected	100	100

Normal serum and plasma samples were tested without dilution prior to the assay.

Parallelism

Serum			EDTA Plasma		
Fold Dilution	Average % Recovery	% Recovery Range	Fold Dilution	Average % Recovery	% Recovery Range
1	72	59-81	1	76	65-88
100	109	101-119	100	112	93-133
1000	NA	NA	1000	254	173-316

Normal human serum and EDTA plasma were tested at different dilutions. Ten-fold diluted samples were tested to determine the expected concentration of the analyte. Samples may benefit from additional dilution with assay diluent to reduce matrix effects. NA = not available.

% Recovery = (measured concentration / expected concentration) x 100

Spike Recovery

Spike Level	Serum		EDTA Plasma	
	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range
High	64	44-81	80	75-86
Mid	83	82-86	87	83-92
Low	82	78-86	82	79-85

Normal serum and plasma were spiked with Calibrator at 3 levels and diluted 4-fold. The expected concentration of the analyte in spiked samples was calculated by addition of the Calibrator spike concentration to the measured endogenous (unspiked) sample concentration.

% Recovery = (measured concentration / expected concentration) x 100

Specificity

To assess specificity, the MIF Antibody Set was tested individually against a larger panel of analytes for nonspecific binding (APRIL/TNFSF13, BAFF-R/TNFRSF13C, BCMA/TNFRSF17, BDNF, C-Peptide, CD20, CD27, CD28, CD40L (soluble), CD276/B7-H3, CTACK, CTLA-4, Desghrelin, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, E-Selectin, FGF (basic), FGF-23, FLT3L, Fractalkine, FSH, Galectin-9, G-CSF, GITRL/TNFSF18, GITR/TNFRSF18, Ghrelin (Ser3-octanoylated), gp130 (soluble), GIP (1–42), GIP (3–42), GLP-1 (7–36), GLP-1 (9–36), GM-CSF, Granzyme A, Granzyme B, GRO-α, HAVCR2/TIM-3, HVEM/TNFRSF14, ICOS, ICOS-L/B7-H2, I-309, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, Insulin, IP-10, LAG3, Leptin, LH, LIGHT/TNFSF14, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIG, MIP-1α, MIP-1β, MIP-5, MMP-1, MMP-2, MMP-7, Nectin-4, OX40/TNFRSF4, PD1, PD-L1, PD-L2, Pentraxin 3, Perforin, PlGF, PP, Proinsulin, proMMP-9, P-Selectin, PYY (3–36), RAGE (soluble), RANKL/TNFSF11, RANTES, S100A12, SDF-1α, Tie-2, TIGIT, TLR1, TNF-α, TNF-β, TNF-RI, TNF-RII, TPO, TRAIL, TSLP, VEGF-A, VEGF-D, VEGFR-1/Flt-1, and YKL-40). Nonspecific binding was less than 2.0%.

% Nonspecificity = (nonspecific signal / specific signal) x 100

Diluent Compatibility

The data included in this document were collected with Assay Diluent 43 and Antibody Diluent 3. Diluent 57 may be provided as an alternate to Diluent 43. MSD offers a range of assay and antibody diluents for separate purchase. Depending on your assay needs, other diluents may be tested.

Assay Components

Calibrator: MIF is included in Calibrator 10 The MIF Calibrator is a full-length recombinant protein expressed in *E. coli*.
Antibodies: The U-PLEX Human MIF Assay uses a mouse monoclonal antibody for capture and a mouse monoclonal antibody for detection.
Assay generation: A

Note: This datasheet contains representative assay performance data. In custom multiplex formats, the assay may perform differently from the representative data shown.

Note: MSD recommends that samples be diluted 100-fold prior to analysis in this assay.